Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025
Compugen (NASDAQ: CGEN) announced a pooled analysis of 60 evaluable patients with platinum resistant ovarian cancer showing COM701 was well tolerated with consistent, durable responses; the abstract was released by ESMO and a poster will be presented on October 18, 2025 in Berlin.
The analysis highlights stronger outcomes particularly in patients without liver metastases and supports testing COM701 as maintenance therapy in earlier, platinum sensitive disease in the ongoing MAIA-ovarian trial. An interim MAIA-ovarian analysis is planned once ~60 participants are evaluable, currently estimated by year-end 2026. Sites are active in the U.S. and Israel, with site activation initiated in France; the company expects cash to fund operations into 2027.
Compugen (NASDAQ: CGEN) ha annunciato un'analisi aggregata di 60 pazienti valutabili con cancro ovarico resistente al platino, che ha mostrato che COM701 è ben tollerato con risposte coerenti e durature; l'abstract è stato rilasciato dall'ESMO e un poster sarà presentato il 18 ottobre 2025 a Berlino.
L'analisi evidenzia esiti più forti soprattutto in pazienti senz liver metastases s mante con i pazienti senza metastasi epatiche e supporta testare COM701 come terapia di mantenimento in malattia precedentemente sensibile al platino, nell'ambito dello studio MAIA-ovarian in corso. Un'analisi intermedia MAIA-ovarian è pianificata una volta che circa 60 partecipanti siano valutabili, attualmente stimata entro la fine del 2026. I siti sono attivi negli USA e in Israele, con l'attivazione dei siti iniziata in Francia; l'azienda prevede che la liquidità finanzierà le operazioni fino al 2027.
Compugen (NASDAQ: CGEN) anunció un análisis agrupado de 60 pacientes evaluables con cáncer de ovario resistente al platino, que mostró que COM701 se toleró bien con respuestas consistentes y duraderas; el resumen fue publicado por ESMO y se presentará un cartel el 18 de octubre de 2025 en Berlín.
El análisis destaca resultados más fuertes especialmente en pacientes sin metástasis hepáticas y apoya probar COM701 como terapia de mantenimiento en la enfermedad previamente sensible al platino en el ensayo MAIA-ovárico en curso. Un análisis intermedio MAIA-ovarian está planificado una vez que ~60 participantes sean evaluables, estimado actualmente para finales de 2026. Los sitios están activos en Estados Unidos e Israel, con la activación de sitios iniciada en Francia; la empresa espera que el efectivo financie las operaciones hasta 2027.
컴퓨젠(나스닥: CGEN)은 평가 가능한 60명의 플래티넘 내성 난소암 환자에 대한 집계 분석을 발표했으며, COM701이 잘 견뎌지고 일관되며 지속적인 반응을 보였다고 밝혔다; 초록은 ESMO에 의해 발표되었고 2025년 10월 18일 베를린에서 포스터가 발표될 예정입니다.
분석은 특히 간 전이가 없는 환자에서 더 강한 결과를 강조하고, MAIA-ovarian 진행 중인 연구에서 초기, 플래티넘에 민감한 질환에서의 유지 치료로 COM701의 테스트를 뒷받침합니다. MAIA-ovarian의 중간 분석은 약 60명의 참가자가 평가 가능해질 때 계획되어 있으며, 현재 2026년 말로 추정됩니다. 미국과 이스라엘의 사이트들이 활성화되어 있으며, 프랑스에서도 사이트 활성화가 시작되었고, 회사는 현금으로 2027년까지 운영 자금을 조달할 것으로 예상합니다.
Compugen (NASDAQ: CGEN) a annoncé une analyse groupée de 60 patients évaluables atteints d'un cancer de l'ovaire résistant au platine, montrant que COM701 est bien toléré avec des réponses constantes et durables; le résumé a été publié par l'ESMO et un poster sera présenté le 18 octobre 2025 à Berlin.
L'analyse met en évidence des résultats plus solides notamment chez les patients sans métastases hépatiques et soutient l'évaluation de COM701 comme thérapie d'entretien dans la maladie auparavant sensible au platine dans l'essai MAIA-ovarian en cours. Une analyse intérimaire MAIA-ovarian est planifiée une fois qu'environ 60 participants seront évaluables, estimé actuellement d'ici la fin de 2026. Les sites sont actifs aux États-Unis et en Israël, avec l'activation des sites démarrée en France; la société s'attend à ce que la trésorerie finance les opérations jusqu'en 2027.
Compugen (NASDAQ: CGEN) kündigte eine konsentierte Analyse von 60 bewerteten Patienten mit platinresistentem Ovarialkarzinom an, die zeigte, dass COM701 gut verträglich war und konsistente, nachhaltige Antworten lieferte; das Abstract wurde von der ESMO veröffentlicht und ein Poster wird am 18. Oktober 2025 in Berlin vorgestellt.
Die Analyse hebt insbesondere bei Patienten ohne Lebermetastasen bessere Ergebnisse hervor und unterstützt die Prüfung von COM701 als Erhaltungstherapie bei einer früheren, platinempfindlichen Erkrankung im laufenden MAIA-ovarian-Studienprogramm. Eine Zwischenanalyse MAIA-ovarian ist geplant, sobald ca. 60 Teilnehmer evaluiert werden können, derzeit bis Ende 2026 vorgesehen. Standorte sind in den USA und Israel aktiv, mit der Aktivierung der Standorte in Frankreich begonnen; das Unternehmen erwartet, dass die Mittel die Operationen bis 2027 finanzieren.
كومبيجين (ناسداك: CGEN) أعلنت عن تحليل مجمع لـ 60 مريضة قابلة للتقييم مصابات بسرطان المبيض المقاوم للبلاتين، مُظهرة أن COM701 مُحتمل تحمّله جيداً مع استجابات ثابتة ومستمرة؛ تم إصدار الملخص من ESMO وسيُعرض ملصق في 18 أكتوبر 2025 في برلين.
يبرز التحليل نتائج أقوى خاصة لدى المرضى بدون نقائل في الكبد ويدعم اختبار COM701 كعلاج حفظ في المرض السابق الحساسية للبلاتين في تجربة MAIA-ovarian الجارية. من المخطط إجراء تحليل وسيطي MAIA-ovarian بمجرد أن يصبح نحو 60 مشاركاً قابلاً للتقييم، وُيَقدر حاليًا أن ذلك سيكون بنهاية 2026. المواقع نشطة في الولايات المتحدة وإسرائيل، مع بدء تفعيل المواقع في فرنسا؛ وتتوقع الشركة أن التمويل النقدي سيغطي العمليات وحتى 2027.
康派根（NASDAQ: CGEN）宣布对 60名可评估患者 的铂耐药性卵巢癌进行的汇总分析，显示 COM701 耐受良好，反应一致且持久；该摘要由 ESMO 发布，海报将于 2025 年 10 月 18 日 在柏林展示。
分析特别在无肝转移的患者中显示出更强的结果，并支持在早期、对铂敏感疾病中将 COM701 作为维持治疗的测试，在正在进行的 MAIA-ovarian 试验中。计划在约 60 名参与者可评估时进行 MAIA-ovarian 的中期分析，当前预计在 2026 年底 完成。研究点在美国和以色列活跃，法国也已启动站点；公司预计现金将资助运营直至 2027 年。
- Pooled analysis includes 60 evaluable patients
- Poster presentation at ESMO on Oct 18, 2025
- MAIA-ovarian interim planned at ~60 participants, estimated year-end 2026
- Sites activated in U.S. and Israel; France activation initiated
- Durable responses concentrated in patients without liver metastases
- Data limited to heavily pretreated platinum-resistant cohort of 60 patients
- Interim MAIA-ovarian readout not expected until year-end 2026
Insights
Pooled Phase 1 data and a planned interim MAIA-ovarian readout strengthen the clinical case for COM701 as earlier‑line maintenance.
Compugen reports a pooled analysis of
The key dependency is whether the pooled efficacy signal (including the reported progression‑free survival characterization) translates to a maintenance benefit in a less heavily pretreated population. Safety and durable responses in a refractory cohort are encouraging but do not by themselves prove benefit in an earlier setting. The planned interim analysis of MAIA‑ovarian once ~
Watch for the interim MAIA‑ovarian analysis timing (company estimates year‑end
- Pooled analysis supports the rationale for the ongoing MAIA-ovarian trial evaluating COM701 as maintenance therapy in the earlier setting of platinum sensitive ovarian cancer
HOLON,
The abstract focuses on a pooled analysis of 60 evaluable patients with platinum resistant ovarian cancer from prior COM701 Phase 1 clinical trials. The analysis characterizes the outcomes of patients who derived clinical benefit including progression free survival data. An additional year of follow-up will be included in the poster. The poster will be presented at ESMO in
"The pooled analysis demonstrates that COM701 was well tolerated and showed consistent, durable responses in patients with heavily pretreated platinum-resistant ovarian cancer - particularly in those without liver metastases, representing patients with lower disease burden and potentially less immunosuppressive tumor microenvironment," said Dr. Oladapo Yeku. "The results of the analysis support the rationale for evaluating COM701 as maintenance therapy in earlier lines of treatment. I look forward to discussing this data along with the ongoing MAIA-ovarian trial in
"There is a gap in care for women with platinum sensitive ovarian cancer who respond to chemotherapy but are ineligible for or cannot tolerate additional maintenance treatment," said Eran Ophir, Ph.D., President, and Chief Executive Officer of Compugen. "These patients have a less compromised immune system, providing the opportunity to harness the unique mechanism of action of COM701 to potentially change the disease trajectory and improve progression free survival. Compugen is currently conducting the MAIA-ovarian trial link assessing COM701 monotherapy as maintenance treatment in relapsed platinum-sensitive ovarian cancer."
Dr. Ophir added, "An interim analysis of the MAIA-ovarian trial is planned once data from approximately 60 participants enable assessment of median progression free survival. Sites have been activated in the
Access the Abstract
The abstract is now available on the publication section of Compugen's website. The poster will be available on the publication section of Compugen's website on Saturday October 18, 2025.
Additional ESMO Highlights
ESMO 2025 will also feature presentations from companies with differentiated Fc-reduced TIGIT programs, including two oral presentations from Compugen's partner AstraZeneca with rilvegostomig- Fc reduced PD1/TIGIT bispecific, the TIGIT component of which is derived from Compugen's clinical stage, COM902.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development, is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen is headquartered in
Forward-Looking Statement
This press release contains "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations, and assumptions of Compugen. Forward-looking statements can be identified using terminology such as "will," "may," "expects," "anticipates," "believes," "potential," "plan," "goal," "estimate," "likely," "should," "confident," and "intends," and similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, statements regarding our providing, and the timing of, an interim analysis of the MAIA-ovarian trial and statements to the effect that our cash will be sufficient to fund our operating plans well into 2027. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance, or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: the clinical trials of any product candidates that Compugen, or any current or future collaborators, may develop may fail to satisfactorily demonstrate safety and efficacy to the FDA, and Compugen, or any collaborators, may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of these product candidates; Compugen's business model is substantially dependent on entering into collaboration agreements with third parties and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model; Compugen's approach to the discovery of therapeutic products is based on its proprietary computational target discovery infrastructure, which is unproven clinically; general market, political and economic conditions in the countries in which Compugen operates, including
Company Contact:
Yvonne Naughton, Ph.D.
Vice President, Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-present-pooled-analysis-of-com701-in-three-phase-1-trials-in-patients-with-platinum-resistant-ovarian-cancer-at-esmo-2025-302581918.html
SOURCE Compugen Ltd.
FAQ
What did Compugen (CGEN) announce about COM701 at ESMO 2025?
How does the ESMO pooled analysis affect the MAIA-ovarian trial (CGEN)?
When does Compugen expect interim MAIA-ovarian (CGEN) results?
How many patients were included in the COM701 pooled analysis reported by Compugen (CGEN)?
Where and when will Compugen present the COM701 poster at ESMO 2025?
Does Compugen (CGEN) have global trial sites for MAIA-ovarian?
